
FOCUS 77L is an NGS-based liquid biopsy assay designed for patients with insufficient tissue for molecular testing, when repeat tissue biopsy is not feasible, and/or in cases of disease progression or suspected acquired resistance. By analyzing ctDNA in blood, it enables longitudinal monitoring of the tumor’s molecular profile.
The assay demonstrates high concordance with tissue-based genomic profiling and, in accordance with international guidelines (ASCO and ESMO), enables the sensitive detection of resistance-associated alterations that may emerge during treatment.
Applications:
Cancer Type: All solid tumors*
* For patients with non-small cell lung cancer (NSCLC) or colorectal cancer (CRC) who have progressive disease and insufficient tissue for molecular analysis, liquid biopsy (cfDNA) is recognized by NCCN Guidelines as a critical diagnostic approach.
Technical Specifications | |
|---|---|
Method: NGS – Hybrid Capture | Coverage: ~10,000x (High Sensitivity) |
Coverage: 77 Genes (Included in NCCN guidelines) ALK, NTRK1, FGFR2, FGFR3, RET, and ROS1 (Fusions); EGFR, ERBB2, and MET (CNVs) genes Genetic Alterations Analyzed: Detects SNV, Indel, Fusion, and CNV variants with a limit of detection (LoD) down to 0.1%. | |
Assay Kit: ROCHE AVENIO ctDNA kit | Sequencing System: Illumina NextSeq 550 DX (CE-IVD approved) |
Bioinformatics System: Avenio | Accreditation: GENQA External Quality Assessment (EQA) & CAP Accreditation |
Other Features: The test features a Positive Predictive Value (PPV) of >99%, significantly minimizing false-positive rates. | |
Sample Requirements: 2 Streck Tubes Turnaround Time (TAT): 10–14 days | |
* Please contact our laboratory for detailed sample submission requirements.
FOCUS 77 Liquid is performed in accordance with the requirements of the EMQN External Quality Assessment (EQA) program.


![]()
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, 34394 Şişli / Istanbul, Turkey
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00